A randomized phase II trial of pemetrexed plus irinotecan (ALIRI) versus leucovorin-modulated 5-FU plus irinotecan (FOLFIRI) in first-line treatment of locally advanced or metastatic colorectal cancer

Oncology

Volumn 73, Issue 1-2, 2008, Pages 9-20

  Underhill, Craig ^a   Goldstein, David ^b,c   Gorbounova, Vera A ^d   Biakhov, Mikhail Y ^e   Bazin, Igor S ^d   Granov, Dmitry A ^f   Hossain, Anwar M ^g   Blatter, Johannes ^g   Kaiser, Christopher ^g   Ma, Doreen ^g  

^a Border Medical Oncology Australia   (Australia)

^b Tamworth Base Hospital   (Australia)

^c PRINCE OF WALES HOSPITAL   (Australia)

^d N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

^e N Semashko Hospital   (Russian Federation)

^f Russian Center for Research in Radiological and Surgical Technologies   (Russian Federation)

^g ELI LILLY AND COMPANY   (United States)

Author keywords

Biomarker; Colorectal carcinoma; Irinotecan; Pemetrexed

Indexed keywords

BIOLOGICAL MARKER; CYANOCOBALAMIN; DEOXYURIDINE TRIPHOSPHATE PYROPHOSPHATASE; FLUOROURACIL; FOLIC ACID; FOLINIC ACID; FOLYLPOLYGLUTAMATE SYNTHASE; IRINOTECAN; PEMETREXED;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DISEASE MARKER; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; GENE EXPRESSION; HUMAN; HYPERTENSION; INFECTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADENOCARCINOMA; ADENOCARCINOMA, MUCINOUS; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; GAMMA-GLUTAMYL HYDROLASE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTAMATES; GUANINE; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDICTIVE VALUE OF TESTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TANDEM REPEAT SEQUENCES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 41549110819     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000120626     Document Type: Article

References (36)

1. Parkin DM, Bray F, Ferlay J, et al: Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Machover D: A comprehensive review of 5-fluorouracil and leucovorin in patients with metastatic colorectal carcinoma. Cancer 1997;80:1179-1187.
3. Holen KD: Target practice: figuring out which, when, and why to use systemic therapies for metastatic colon cancer. Cancer Invest 2006;24:98-105.
4. Saltz LB, Cox JV, Blanke C, et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343:905-914.
5. Douillard JY, Cunningham D, Roth AD, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355:1041-1047. Erratum 355:1372.
6. Pizzolato JF, Saltz LB: The camptothecins. Lancet 2003;361:2235- 2242.
7. Tournigand C, Andre T, Achille E, et al: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22:229-237.
8. John W, Picus J, Blanke CD, et al: Activity of multitargeted antifolate (pemetrexed disodium, pemetrexed) in patients with advanced colorectal carcinoma. Cancer 2000;88:1807-1813.
9. Hochster H, Kettner E, Kroning H, et al: Phase I/II dose-escalation study of pemetrexed plus irinotecan in patients with advanced colorectal cancer. Clin Colorectal Cancer 2005;5:257-262.
10. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-216.
11. Pocock SJ, Simon R: Sequential treatment assignment with balancing of prognostic factors in controlled clinical trials. Biometrics 1975;31:103-115.
12. Cancer Therapy Evaluation Program. Common Toxicity Criteria, Version 2.0. DCTD, NCI, NIH, DHHS, 1998.
13. Leemis LM, Trivedi KS: A comparison of approximate interval estimators for the Bernoulli parameter. Am Stat 1996;50:63-68.
14. Kaplan EL, Meier P: Nonparametric estimation of incomplete observations. J Am Stat Assoc 1958;53:457-481.
15. Cox DR: Regression models and life tables (with discussion). J R Stat Soc Ser B 1972;34:187-220.
16. Miller R, Siegmund D: Maximally selected chi square statistics. Biometrics 1982;38:1011-1016.
17. Ladner RD, Lynch FJ, Groshen S, Xiong YP, Sherrod A, Caradonna SJ, Stoehlmacher J, Lenz HJ: dUTP nucleotidohydrolase isoform expression in normal and neoplastic tissues: association with survival and response to 5-fluorouracil in colorectal cancer. Cancer Res 2000;60:3493-3503.
18. Kohne CH, Cunningham D, Di CF, et al: Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol 2002;13:308-317.
19. Shirota Y, Stoehlmacher J, Brabender J, et al: ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 2001;19:4298-4304.
20. Kralovanszky J, Koves I, Orosz Z, et al: Prognostic significance of the thymidylate biosynthetic enzymes in human colorectal tumors. Oncology 2002;62:167-174.
21. van Triest B, Pinedo HM, van Hensbergen Y, et al: Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines. Clin Cancer Res 1999;5:643-654.
22. Johnston PG, Benson AB 3rd, Catalano P, et al: Thymidylate synthase protein expression in primary colorectal cancer: lack of correlation with outcome and response to fluorouracil in metastatic disease sites. J Clin Oncol 2003;21:815-819.
23. Tai N, Schmitz JC, Liu J, et al: Translational autoregulation of thymidylate synthase and dihydrofolate reductase. Front Biosci 2004;9:2521-2526.
24. Salonga D, Danenberg KD, Johnson M, et al: Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 2000;6:1322-1327.
25. Mariadason JM, Arango D, Shi Q, et al: Gene expression profiling-based prediction of response of colon carcinoma cells to 5-fluorouracil and camptothecin. Cancer Res 2003;63:8791-8812.
26. Kidd EA, Yu J, Li X, et al: Variance in the expression of 5-fluorouracil pathway genes in colorectal cancer. Clin Cancer Res 2005;11:2612-2619.
27. Gomez HL, Santillana SL, Vallejos CS, et al: A phase II trial of pemetrexed in advanced breast cancer: clinical response and association with molecular target expression. Clin Cancer Res 2006;2:832-838.
28. Mattison LK, Fourie J, Desmond RA, et al: Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians. Clin Cancer Res 2006;12:5491-5495.
29. Schneider E, Ryan TJ: Gamma-glutamyl hydrolase and drug resistance. Clin Chim Acta 2006;374:25-32.
30. Van Triest B, Pinedo HM, Giaccone G, et al: Downstream molecular determinants of response to 5-fluorouracil and antifolate thymidylate synthase inhibitors. Ann Oncol 2000;11:385-391.
31. Smorenburg CH, Peters GJ, van Groeningen, et al: Phase II study of tailored chemotherapy for advanced colorectal cancer with either 5-fluouracil and leucovorin or oxaliplatin and irinotecan based on the expression of thymidylate synthase and dihydropyrimidine dehydrogenase. Ann Oncol 2006;17:35-42.
32. Kawakami K, Salonga D, Park JM, et al: Different lengths of a polymorphic repeat sequence in the thymidylate synthase gene affect translational efficiency but not its gene expression. Clin Cancer Res 2001;7:4096-4101.
33. Moisan F, Longy M, Robert J, et al: Identification of gene polymorphisms of human DNA topoisomerase I in the National Cancer Institute panel of human tumour cell lines. Br J Cancer 2006;95:906-913.
34. Locker GY, Hamilton S, Harris J, et al: ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006;24:5313-5327.
35. Arango D, Corner GA, Wadler S, et al: cmyc/ p53 interaction determines sensitivity of human colon carcinoma cells to 5-fluorouracil in vitro and in vivo. Cancer Res 2001;61:4910-4915.
36. Vallbohmer D, Iqbal S, Yang DY, et al: Molecular determinants of irinotecan efficacy. Int J Cancer 2006;19:2435-2442.